TOP > 外国特許検索 > DRUG FOR REMOVING AGED CELLS

DRUG FOR REMOVING AGED CELLS

外国特許コード F180009352
整理番号 (S2016-0978-N0)
掲載日 2018年4月18日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP030867
国際公開番号 WO 2018043463
国際出願日 平成29年8月29日(2017.8.29)
国際公開日 平成30年3月8日(2018.3.8)
優先権データ
  • 特願2016-167679 (2016.8.30) JP
発明の名称 (英語) DRUG FOR REMOVING AGED CELLS
発明の概要(英語) Provided is a drug for removing aged cells or a medicinal composition therefor, said drug or composition comprising an SGLT2 inhibitor.
特許請求の範囲(英語) [claim1]
1. SGLT2 blocker, aging cell removal agent.
[claim2]
2. SGLT2 inhibitors, low molecular weight compound, and a specific binding substance SGLT2 SGLT2 expression inhibitor is selected from the group consisting of at least one of 1, according to claim 1 aging cell removal agent.
[claim3]
3. SGLT2 inhibitor, , empagliflozin, lee plug li furojin, dapagliflozin, ruse oguri furojin, tofogliflozin, sergliflozin etabonate, les diving furojin etabonate, ore glyph rosin, sotagliifuzin, and a pharmaceutically acceptable salt is selected from the group consisting of at least one of 1, aging of claims 1 or 2 cell removal agent.
[claim4]
4. And a pharmaceutically acceptable SGLT2 inhibitor containing carrier, a pharmaceutical composition for removing cell aging.
[claim5]
5. Aging by removing cells is expected to be reduced itnot for preventing or treating diseases, a pharmaceutical composition according to claim 4.
[claim6]
6. Removing cells aging by an aging-related disease is expected to be reduced condition is a disease, a pharmaceutical composition according to claim 5.
[claim7]
7. And a pharmaceutically acceptable SGLT2 inhibitor containing carrier, an aging-related disease prevention or treatment of a pharmaceutical composition to be used for.
[claim8]
8. Age-related disease, heart failure, atherosclerosis, cardiovascular disease cerebral artery disease, hypertension, cerebral infarction, cerebral hemorrhage, dyslipidemic, pulmonary fibrosis, pulmonary emphysema, skeletal muscle atrophies (sarcopenia), osteoarthritis, dementia, flail, cancer, chronic kidney disease, cataract, glaucoma, age-related macular degeneration, presbyopia, epilating age, age-related hearing loss, lumbago due to aging, such as arthralgias pain, sebaseous-deficient eczemas, skin pruritis, fatty liver, nonalcoholic steatohepatitis (NASH), cirrhosis, osteoporosis, deformation of osteoarthritis, hutchinson, guildford, progeria syndrome, werner syndrome, moss-syndrome, and , at least one selected from the group consisting of 1 Thomson syndrome is one of, wherein the pharmaceutical composition of claims 6 or 7.
[claim9]
9. SGLT2 inhibitor, , empagliflozin, lee plug li furojin, dapagliflozin, ruse oguri furojin, tofogliflozin, sergliflozin etabonate, les diving furojin etabonate, ore glyph rosin, sotagliifuzin, and a pharmaceutically acceptable salt is selected from at least one of 1, any one of claims 4-8 pharmaceutical composition.
[claim10]
10. In the manufacture of a medicament for the removed cell senescence, use SGLT2 inhibitor.
[claim11]
11. Aging by removing cells is expected to be reduced itnot preventing or treating diseases in the manufacture of a medicament for, use SGLT2 inhibitor.
[claim12]
12. Aging method for removing cells, an effective amount of a SGLT2 inhibitor, which comprises administering to a subject in need, method.
[claim13]
13. Aging by removing cells is expected to be reduced itnot for preventing or treating diseases method, an effective amount of an inhibitor SGLT2, administering to a subject in need thereof comprising, method.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • MITSUBISHI TANABE PHARMA CORPORATION
  • 発明者(英語)
  • MINAMINO TOHRU
国際特許分類(IPC)
指定国 (WO201843463)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close